Business Context and Reporting Period
This Form 8-K Current Report was filed by Propanc Health Group Corporation (also referred to as Propanc Biopharma, Inc.) on December 7, 2016, covering events occurring on December 1 and December 2, 2016. The filing details the entry into material definitive agreements and the creation of direct financial obligations with two investors: Delafield Investments Limited and GHS Investments LLC.
Key Financial Metrics and Obligations
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, or margins. Instead, it outlines specific capital structure changes and new debt instruments:
- Delafield Note: A new 8% convertible redeemable promissory note issued in the principal amount of $150,000, maturing two years from issuance.
- GHS Note: A $250,000 junior subordinated promissory note issued to GHS Investments LLC, accruing interest at 10% per annum, maturing nine months from issuance.
- Commitment Note: A $20,000 unsecured junior subordinated promissory note issued to GHS, accruing interest at 5% per annum, maturing six months from issuance.
- Equity Financing Capacity: An agreement allowing the Company to sell up to $7.0 million of common stock to GHS via put notices following the effectiveness of a resale registration statement.
Material Changes Versus Prior Period
The filing reports significant restructuring of existing securities and the issuance of new instruments:
- Warrant Cancellation: The Company cancelled two previously issued warrants held by Delafield: a two-year warrant for 40,000,000 shares at $0.10/share and a five-month warrant for up to 200,000,000 shares at prices between $0.012 and $0.020/share.
- Share Redemption: The Company redeemed 12,500,000 restricted shares held by Delafield (originally purchased for $150,000) in exchange for the new $150,000 Delafield Note.
- New Warrant Issuance: In connection with the Delafield agreement, the Company issued a new two-year warrant to purchase 26,000,000 shares at an exercise price of $0.05 per share.
- Debt Restructuring Consents: Delafield provided consents and waivers regarding the Company's compliance with a $4,400,000 2015 Debenture and a $165,000 Additional Issuance Debenture.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance regarding revenue or earnings. However, it outlines specific terms and risks associated with the new financing arrangements:
- Conversion Discounts: The Delafield Note converts at 65% of the average of the three lowest closing bid prices. The GHS Note converts at a 30% discount (or 35% if registration is delayed) to the lowest trading price.
- Prepayment Penalties: The Delafield Note may be prepaid at 135% of principal plus interest. The GHS Note has tiered prepayment penalties ranging from 125% to 135% depending on the timing.
- Default Provisions: Upon default, the Delafield Note accrues interest at 18% per annum. The GHS Note accelerates at 150% of amounts owed with a 20% default interest rate.
- Put Mechanism Risks: The GHS financing agreement includes a "put" mechanism where the Company can force GHS to buy shares. The price is generally 80% of the average of the three lowest VWAPs, with a floor of $0.01. There is a downside protection mechanism for GHS if the stock price drops significantly after a put notice.
Investor Verification Checklist
- Verify the status of the Resale Registration Statement required to activate the $7.0 million put facility with GHS.
- Confirm the outstanding balance and interest accrual on the existing $4,400,000 2015 Debenture and $165,000 Additional Issuance Debenture.
- Assess the dilution impact of the new 26,000,000 share warrant issued to Delafield and the potential conversion of the $400,000 in new notes.
- Review the Company's liquidity position to ensure it can meet potential prepayment penalties or default acceleration clauses if cash flow is constrained.
- Check for any subsequent filings regarding the effectiveness of the registration statement or the delivery of put notices to GHS.